Gpr109a alleviates mammary fibrosis via PPARγ-mediated reduction of ROS and mitochondrial damage
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115603 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Junlong Bi und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Veterinary Medicine, Yunnan Agricultural University, Kunming, Yunnan 650201, China. Hauptthemen laut MEDLINE: PPAR gamma, Receptors, G-Protein-Coupled, Reactive Oxygen Species, Mitochondria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Mammary fibrosis is a serious pathological process, which seriously threatens life and health. Gpr109a is a membrane receptor that has been reported to be protective in liver/lung fibrosis, but the mechanism of mammary tissue specificity still needs to be verified. Therefore, the purpose of this experiment was to explore the effect of Gpr109a on mammary fibrosis and its potential regulatory mechanism. The results show that Gpr109a deletion exacerbates the TGF-β induced mouse mammary fibrosis phenotype and mitochondrial damage (including mitochondrial nuclear shrinkage, cristae reduction, membrane potential decrease, and ATP reduction, etc.). However, backfilling of Gpr109a could effectively reverse the above experimental results. RNA-seq results of mice mammary gland tissue showed that Gpr109a knock-out significantly affect PPARγ signaling, which may be an important signal for alleviating fibrosis. Mechanistic results showed that silencing of PPARγ significantly blocked the alleviation effect of Gpr109a on mitochondrial damage and elevated fibrotic phenotype indicators in mMECs. However, activating PPARγ effectively reversed the above experimental phenomena. Further studies found that PPARγ alleviated mammary tissue fibrosis and mitochondrial damage by reducing ROS accumulation. In conclusion, Gpr109a/PPARγ signaling reduces the tendency of mammary fibrosis by reducing the accumulation of ROS and mitochondrial damage, suggesting that Gpr109a has the potential to become an anti-mammary fibrosis target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Animal Veterinary Medicine, Yunnan Agricultural University, Kunming, Yunnan 650201, China.
- College of Veterinary Medicine, Jilin University, Changchun, 130000, Jilin, China.
- Shanghai Animal Disease Control Center, Lane 855, Hongjing Road, Changning District, Shanghai 201103, China.
- Xianghu Laboratory, Hangzhou 311231, China; College of Veterinary Medicine, Jilin University, Changchun, 130000, Jilin, China; Zhejiang Lab, Kechuang Avenue, Hangzhou, 311121, Zhejiang, China. Electronic address: kanxin…
- College of Animal Veterinary Medicine, Yunnan Agricultural University, Kunming, Yunnan 650201, China. Electronic address: 1997015@ynau.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bi, J., He, D., Li, F., Xu, P., Huang, Y., Guo, W., Fu, S., Kan, X., & Li, Y. (2025). Gpr109a alleviates mammary fibrosis via PPARγ-mediated reduction of ROS and mitochondrial damage. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115603
Vancouver
Bi J, He D, Li F, Xu P, Huang Y, Guo W, et al. Gpr109a alleviates mammary fibrosis via PPARγ-mediated reduction of ROS and mitochondrial damage. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115603
BibTeX
@article{Bi2025,
author = {Bi, Junlong and He, Dewei and Li, Feng and Xu, Ping and Huang, Yaping and Guo, Wenjin and Fu, Shoupeng and Kan, Xingchi and Li, Yongneng},
title = {Gpr109a alleviates mammary fibrosis via PPARγ-mediated reduction of ROS and mitochondrial damage},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115603}
}
EUVIMED